


To: 5.1.2e [5.1.2e]@rivm.nl]
From: AstraZeneca
Sent: Thur 2/10/2022 7:01:49 AM
Subject: Full-year and Q4 2021 results
Received: Thur 2/10/2022 7:02:09 AM

[Click here to view online.](#) [Add this email to your safelist.](#)



Full-year and Q4 2021 results

10 February 2022

"AstraZeneca continued on its strong growth trajectory in 2021, with industry-leading R&D productivity, five of our medicines crossing new blockbuster thresholds, and the acquisition and integration of Alexion. We also delivered on our promise of broad and equitable access to our COVID-19 vaccine with 2.5 billion doses released for supply around the world, and we made good progress on reducing our greenhouse gas emissions."

Read more



[RSS Feed](#)



[Follow us on Twitter](#)



[Follow us on LinkedIn](#)

[Legal notice and Terms of Use](#) | [Privacy policy](#) | [Cookie policy](#) | [Site map](#) | © AstraZeneca 2022

For more information please visit astrazeneca.com.

If you would like to unsubscribe please [click here](#).